M1 muscarinic acetylcholine receptor in Alzheimer's disease  

作　　者：Shangtong Jiang Yanfang Li Cuilin Zhang Yingjun Zhao Guojun Bu Huaxi Xu Yun-Wu Zhang 

机构地区：[1]Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University [2]School of Pharmaceutical Sciences, Xiamen University [3]Degenerative Disease Research Program, Sanford-Burnham Medical Research Institute

出　　处：《Neuroscience Bulletin》2014年第2期295-307,共13页神经科学通报（英文版）

基　　金：supported by grants from the National Institutes of Health,USA(R01AG038710,R01AG021173,R01AG044420 and R01NS046673);the Alzheimer’s Association,the National Natural Science Foundation of China(91332112,81225008 and 81161120496);Fundamental Research Funds for the Central Universities of China;the Fok Ying Tung Education Foundation

摘　　要：The degeneration of cholinergic neurons and cholinergic hypofunction are pathologies associated with Alzheimer＇s disease （AD）. Muscarinic acetylcholine receptors （mAChRs） mediate acetylcholine-induced neurotransmission and five mAChR subtypes （M1-M5） have been identified. Among them, M1 mAChR is widely expressed in the central nervous system and has been implicated in many physiological and pathological brain functions. In addition, M1 mAChR is postulated to be an important therapeutic target for AD and several other neurodegenerative diseases. In this article, we review recent progress in understanding the functional involvement of M1 mAChR in AD pathology and in developing M1 mAChR agonists forAD treatment.The degeneration of cholinergic neurons and cholinergic hypofunction are pathologies associated with Alzheimer＇s disease （AD）. Muscarinic acetylcholine receptors （mAChRs） mediate acetylcholine-induced neurotransmission and five mAChR subtypes （M1-M5） have been identified. Among them, M1 mAChR is widely expressed in the central nervous system and has been implicated in many physiological and pathological brain functions. In addition, M1 mAChR is postulated to be an important therapeutic target for AD and several other neurodegenerative diseases. In this article, we review recent progress in understanding the functional involvement of M1 mAChR in AD pathology and in developing M1 mAChR agonists forAD treatment.

关 键 词：AGONIST Alzheimer＇s disease AMYLOID cholinergic hypofunction M1 muscarinic acetylcholinereceptor tau 

分 类 号：R749.16[医药卫生—神经病学与精神病学]